Is MCRB or NKTX more profitable?

Nkarta has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Nkarta's return on equity of -39.64% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics -1,192.94% -114.82% -34.15% Nkarta N/A -39.64% -30.45%

Does the media prefer MCRB or NKTX?

In the previous week, Seres Therapeutics and Seres Therapeutics both had 3 articles in the media. Nkarta's average media sentiment score of 0.99 beat Seres Therapeutics' score of 0.22 indicating that Nkarta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nkarta 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, ADAG or MCRB?

Seres Therapeutics has lower revenue, but higher earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 31.78 -$17.61M N/A N/A Seres Therapeutics $790K 71.75 $5.70M -$2.43 N/A

Does the media refer more to MCRB or HUMA?

In the previous week, Seres Therapeutics had 1 more articles in the media than Humacyte. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for Humacyte. Humacyte's average media sentiment score of 0.56 beat Seres Therapeutics' score of 0.22 indicating that Humacyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Humacyte 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MCRB or CYPH?

In the previous week, Seres Therapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.28 beat Seres Therapeutics' score of 0.22 indicating that Cypherpunk Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cypherpunk Technologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Seres Therapeutics (MCRB) Competitors

$5.64 +0.10 (+1.81%)

As of 04:00 PM Eastern

Compare

MCRB vs. NKTX, ADAG, HUMA, CRBU, and CYPH

Should you buy Seres Therapeutics stock or one of its competitors? Seres Therapeutics's main competitors and comparable companies include Nkarta (NKTX), Adagene (ADAG), Humacyte (HUMA), Caribou Biosciences (CRBU), and Cypherpunk Technologies (CYPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Seres Therapeutics compare to Nkarta?

Seres Therapeutics (NASDAQ:MCRB) and Nkarta (NASDAQ:NKTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Seres Therapeutics presently has a consensus target price of $17.00, indicating a potential upside of 201.42%. Nkarta has a consensus target price of $11.20, indicating a potential upside of 301.43%. Given Nkarta's stronger consensus rating and higher probable upside, analysts clearly believe Nkarta is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nkarta	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Seres Therapeutics has higher revenue and earnings than Nkarta. Seres Therapeutics is trading at a lower price-to-earnings ratio than Nkarta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	71.75	$5.70M	-$2.43	N/A
Nkarta	N/A	N/A	-$104.08M	-$1.57	N/A

Nkarta has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Nkarta's return on equity of -39.64% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Nkarta	N/A	-39.64%	-30.45%

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 80.5% of Nkarta shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by company insiders. Comparatively, 9.8% of Nkarta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Seres Therapeutics and Seres Therapeutics both had 3 articles in the media. Nkarta's average media sentiment score of 0.99 beat Seres Therapeutics' score of 0.22 indicating that Nkarta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nkarta	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Nkarta has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

Summary

Nkarta beats Seres Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Adagene?

Adagene (NASDAQ:ADAG) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, media sentiment, earnings, analyst recommendations, valuation and profitability.

Adagene has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

9.5% of Adagene shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 5.2% of Seres Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Adagene currently has a consensus price target of $10.00, indicating a potential upside of 171.00%. Seres Therapeutics has a consensus price target of $17.00, indicating a potential upside of 201.42%. Given Seres Therapeutics' higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Adagene has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Adagene's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Seres Therapeutics has lower revenue, but higher earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	31.78	-$17.61M	N/A	N/A
Seres Therapeutics	$790K	71.75	$5.70M	-$2.43	N/A

In the previous week, Seres Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 3 mentions for Seres Therapeutics and 0 mentions for Adagene. Seres Therapeutics' average media sentiment score of 0.22 beat Adagene's score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Seres Therapeutics	Neutral

Summary

Adagene beats Seres Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Humacyte?

Seres Therapeutics (NASDAQ:MCRB) and Humacyte (NASDAQ:HUMA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Seres Therapeutics has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

Seres Therapeutics has a net margin of -1,192.94% compared to Humacyte's net margin of -4,556.29%. Seres Therapeutics' return on equity of -114.82% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Humacyte	-4,556.29%	-983.32%	-88.84%

Seres Therapeutics has higher earnings, but lower revenue than Humacyte. Seres Therapeutics is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	71.75	$5.70M	-$2.43	N/A
Humacyte	$2.04M	81.16	-$40.83M	-$0.49	N/A

Seres Therapeutics currently has a consensus price target of $17.00, suggesting a potential upside of 201.42%. Humacyte has a consensus price target of $6.54, suggesting a potential upside of 997.60%. Given Humacyte's stronger consensus rating and higher probable upside, analysts clearly believe Humacyte is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Humacyte	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Seres Therapeutics had 1 more articles in the media than Humacyte. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for Humacyte. Humacyte's average media sentiment score of 0.56 beat Seres Therapeutics' score of 0.22 indicating that Humacyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Humacyte beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to Caribou Biosciences?

Seres Therapeutics (NASDAQ:MCRB) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

Seres Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market.

Seres Therapeutics currently has a consensus target price of $17.00, indicating a potential upside of 201.42%. Caribou Biosciences has a consensus target price of $7.75, indicating a potential upside of 393.63%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Caribou Biosciences has a net margin of -1,030.42% compared to Seres Therapeutics' net margin of -1,192.94%. Caribou Biosciences' return on equity of -89.11% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Seres Therapeutics had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Seres Therapeutics and 0 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 1.00 beat Seres Therapeutics' score of 0.22 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Seres Therapeutics	Neutral
Caribou Biosciences	Positive

Seres Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Seres Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	71.75	$5.70M	-$2.43	N/A
Caribou Biosciences	$11.16M	15.08	-$148.12M	-$1.08	N/A

Summary

Caribou Biosciences beats Seres Therapeutics on 13 of the 17 factors compared between the two stocks.

How does Seres Therapeutics compare to Cypherpunk Technologies?

Seres Therapeutics (NASDAQ:MCRB) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Seres Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cypherpunk Technologies has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. Cypherpunk Technologies' return on equity of -20.76% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

Seres Therapeutics has higher revenue and earnings than Cypherpunk Technologies. Seres Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	71.75	$5.70M	-$2.43	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	4.05

Seres Therapeutics presently has a consensus price target of $17.00, indicating a potential upside of 201.42%. Cypherpunk Technologies has a consensus price target of $1.60, indicating a potential downside of 29.52%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Seres Therapeutics had 1 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 0.28 beat Seres Therapeutics' score of 0.22 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cypherpunk Technologies	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Seres Therapeutics beats Cypherpunk Technologies on 8 of the 15 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$55.65M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-2.32	12.66	273.28	25.38
Price / Sales	71.75	1,309.16	613.48	92.60
Price / Cash	5.10	106.87	77.82	52.26
Price / Book	1.64	16.29	12.89	6.14
Net Income	$5.70M	-$22.72M	$3.47B	$349.01M
7 Day Performance	13.94%	-1.37%	-0.33%	-1.47%
1 Month Performance	12.13%	11.07%	6.51%	2.47%
1 Year Performance	-69.51%	53.71%	25.19%	15.84%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	2.5173 of 5 stars	$5.64 +1.8%	$17.00 +201.4%	-71.6%	$55.65M	$790K	N/A	330	News Coverage High Trading Volume
NKTX Nkarta	3.5452 of 5 stars	$2.67 +3.1%	$11.20 +319.5%	+31.9%	$189.87M	N/A	N/A	140	News Coverage Gap Down
ADAG Adagene	3.0425 of 5 stars	$3.95 +1.3%	$10.00 +153.2%	+74.1%	$187.14M	$7.67M	N/A	260	Gap Up
HUMA Humacyte	2.8547 of 5 stars	$0.69 +3.6%	$6.11 +790.3%	-60.5%	$179.58M	$2.12M	N/A	150
CRBU Caribou Biosciences	1.8227 of 5 stars	$1.71 +4.5%	$7.75 +352.2%	-14.9%	$178.50M	$10.04M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. NKTX, ADAG, HUMA, CRBU, and CYPH

How does Seres Therapeutics compare to Nkarta?

Summary

How does Seres Therapeutics compare to Adagene?

Summary

How does Seres Therapeutics compare to Humacyte?

Summary

How does Seres Therapeutics compare to Caribou Biosciences?

Summary

How does Seres Therapeutics compare to Cypherpunk Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. NKTX, ADAG, HUMA, CRBU, and CYPH

How does Seres Therapeutics compare to Nkarta?

Do analysts prefer MCRB or NKTX?

Which has better earnings & valuation, MCRB or NKTX?

Is MCRB or NKTX more profitable?

Do insiders & institutionals believe in MCRB or NKTX?

Does the media prefer MCRB or NKTX?

Which has more volatility and risk, MCRB or NKTX?

Summary

How does Seres Therapeutics compare to Adagene?

Which has more volatility & risk, ADAG or MCRB?

Do insiders and institutionals believe in ADAG or MCRB?

Do analysts recommend ADAG or MCRB?

Is ADAG or MCRB more profitable?

Which has preferable earnings & valuation, ADAG or MCRB?

Does the media favor ADAG or MCRB?

Summary

How does Seres Therapeutics compare to Humacyte?

Which has more risk & volatility, MCRB or HUMA?

Is MCRB or HUMA more profitable?

Which has stronger valuation and earnings, MCRB or HUMA?

Do analysts rate MCRB or HUMA?

Do insiders & institutionals have more ownership in MCRB or HUMA?

Does the media refer more to MCRB or HUMA?

Summary

How does Seres Therapeutics compare to Caribou Biosciences?

Which has more risk & volatility, MCRB or CRBU?

Do analysts prefer MCRB or CRBU?

Is MCRB or CRBU more profitable?

Do insiders and institutionals have more ownership in MCRB or CRBU?

Does the media refer more to MCRB or CRBU?

Which has stronger earnings and valuation, MCRB or CRBU?

Summary

How does Seres Therapeutics compare to Cypherpunk Technologies?

Which has more volatility & risk, MCRB or CYPH?

Do institutionals & insiders have more ownership in MCRB or CYPH?

Is MCRB or CYPH more profitable?

Which has better valuation and earnings, MCRB or CYPH?

Do analysts prefer MCRB or CYPH?

Does the media refer more to MCRB or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools